INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2004

Oral NADH supplementation for 6 months prevented cognitive decline and improved total MDRS scores in patients with Alzheimer's disease.

A 6-month randomized, double-blind, matched-pairs trial evaluated 10 mg/day of stabilized oral NADH versus placebo in 26 patients with probable Alzheimer's disease. After 6 months, patients taking NADH showed no evidence of progressive cognitive deterioration and achieved significantly higher total scores on the MDRS compared with placebo (p < 0.05). Subscale analysis showed significantly better performance with NADH in verbal fluency (p = 0.019) and visual-constructional ability (p = 0.038), with a trend in abstract verbal reasoning (p = 0.08). No differences were found between groups for attention, memory, or Clinical Dementia Rating scores.

Study type
Randomized, placebo-controlled, matched-pairs, double-blind trial
Who was studied
26 patients with probable Alzheimer's disease (12 matched pairs evaluated)
What was measured
Cognitive functioning measured by Mattis Dementia Rating Scale (MDRS) and subscales

THE PAPER

Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.

Demarin V, Podobnik SS, Storga-Tomic D, Kay G. Drugs Exp Clin Res, 2004.

PubMed 15134388 ↗

Nutrients & adequacyBrain & moodHealthy aging & longevity

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.